Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:brand |
gptkb:Abecma
|
| gptkbp:developer |
gptkb:bluebird_bio
gptkb:Bristol_Myers_Squibb |
| https://www.w3.org/2000/01/rdf-schema#label |
Idecabtagene vicleucel
|
| gptkbp:indication |
relapsed or refractory multiple myeloma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells
targets B-cell maturation antigen (BCMA) |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
infections neutropenia neurotoxicity thrombocytopenia cytokine release syndrome |
| gptkbp:source |
autologous T cells
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:treatment |
personalized medicine
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:CAR-T_cell_therapies
|
| gptkbp:bfsLayer |
6
|